In BRCA-deficient ovarian cancer and triple-negative breast cancer mouse models, Olaparib can activate the cGAS/STING pathway in tumor cells, thereby activating TBK1/IRF3 signaling in DCs (146). Here, CGAS is linked to ovarian cancer.